Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine and cyclophosphamide (BEAC). The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 32% (95% confidence interval; 18-45%) with a median follow-up of 3.6 years (range 7 months-7.6 years). The most significant predictor of improved survival was the presence of minimal disease (defined as all areas р2 cm) at the time of transplant: the 5 years EFS was 46 vs 10% for patients with bulky disease (P = 0.0002). Other independent predictors identified by step-wise regression analysis included the presence of non-refractory disease and the administration of posttransplant involved-field radiotherapy (XRT). Treatment-related mortality occurred in 13 of 70 patients: nine patients (13%) died within the first 100 days, mainly from cardiopulmonary toxicity. However, only one of 24 patients (4%) transplanted during the last 4.5 years died from early treatment-related complications. While high-dose therapy followed by autotransplantation led to long-term EFS of 50% for patients with favorable prognostic factors, a substantial proportion of patients relapsed, indicating that new therapeutic strategies are needed.
1
High-dose chemoradiotherapy followed by marrow or blood stem cell rescue has improved the long-term eventfree survival for patients with relapsed or refractory Hodgkin's disease. Many series with different lengths of followup have reported event-free survival rates ranging from 30 to 64%. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A previous report from this institution described 47 consecutive patients with relapsed or refractory HD who received high-dose chemotherapy using primarily the BEAC regimen, followed by autologous stem-cell rescue. 11 This report significantly updates the survival of these patients and includes an additional 23 patients. The effects of post-transplant involved-field radiotherapy and other potential prognostic factors were also examined.
Patients and methods

Patients
Seventy patients with relapsed or refractory HD had autotransplants between February 1989 and December 1996. Characteristics of the study patients are given in Table 1 . Patients were defined to have refractory or non-refractory disease based on the length of remission (if any) that preceeded the relapse that led to transplant. Patients with a remission duration of less than 1 month were considered to have refractory disease, while those with remission durations of 1 month or longer were considered to have nonrefractory disease. Prior to transplant, patients were treated with one to three cycles of dexamethasone, high-dose cytarabine and cisplatin or carboplatin (DHAP), 13 or one of several other regimens, until a CR was obtained or there were no significant changes on successive radiographs or clinical examinations. A reduction of у50% in the volume of the dominant tumour mass (as measured by CT or MRI scans or clinical examination) was defined as a positive treatment response, while a reduction of Ͻ50% was defined as a negative response. Two patients were not evaluable for response to further therapy. After completion of pre-transplant cytoreductive therapy, patients were stratified according to pretransplant disease status. Patients with minimal disease had the following: (1) all nodal areas р2 cm in maximal diameter; (2) extranodal disease confined to a sin- XRT = involved-field radiation therapy; Bu = busulfan; Cy = cyclophosphamide; BEAC = (carmustine, etoposide, cytarabine, cyclophosphamide).
gle organ and containing a single tumor р2 cm in maximal diameter; (3) marrow involvement р20% marrow cellularity; (4) no active CNS involvement. All other patients were considered to have bulky disease. In addition, patients with diffuse or multifocal involvement (у2 sites) of a single extranodal tissue or any measurable involvement of more than one extranodal tissue were considered to have bulky disease. All patients gave written informed consent to undergo autotransplantation.
Preparative regimens
Of the 70 patients in this series, 65 (93%) received the BEAC conditioning regimen: BCNU 300 mg/m 2 on day Ϫ7, etoposide 100 mg/m 2 twice daily on days Ϫ6 to Ϫ3, cytarabine 100 mg/m 2 twice daily on days Ϫ6 to Ϫ3, and cyclophosphamide 35 mg/kg on days Ϫ6 to Ϫ3. Four patients received 12-14 Gy of total body irradiation in six to eight fractions, combined with cyclophosphamide (50 mg/kg for 2 days). The chest was shielded to limit the total lung dose to 7-8 Gy, and the chest wall was treated with an electron beam. One patient received a preparative regimen of busulfan (4 mg/kg for 4 days) and cyclophosphamide (50 mg/kg for 2 days). Since 1991, chemotherapy calculations were based on the lesser of the actual body weight or the ideal body weight. If patients were у30% above their ideal body weight, an adjusted ideal body weight (ideal ϩ 25% of difference between ideal and actual) was used. All patients received intravenous hydration and either saline bladder irrigation through a three-way bladder catheter or mercaptoethane sulfonate sodium (MESNA) (1 mg MESNA/1 mg cyclophosphamide) by continuous intravenous infusion beginning 3 h before cyclophosphamide therapy and ending 24 h after completion. 14 Most of the PBSC products were collected after mobilization, using 3 g/m 2 of cyclophosphamide over 2 days followed by GM-CSF, G-CSF, G ϩ GM-CSF, or PIXY-321, as previously described. 15 
Stem cells
Supportive care
Patients received care in individual rooms equipped with high efficiency particulate air (HEPA) filtration units. Patients received prophylactic acyclovir if herpes simplex virus (HSV) serologies were positive. Empiric broad-spectrum antibacterial agents (generally a semisynthetic penicillin and aminoglycoside) were administered for neutropenic febrile episodes. Amphotericin B was begun if patients became febrile a second time or if the initial fever (у38°C) persisted despite 48 to 72 h of antibacterial therapy. Patients were transfused with irradiated blood products to keep the hematocrit у25% and the platelet count у20 000/mm 3 . Beginning in April 1991, patients received hemopoietic growth factors after stem-cell infusion. This generally consisted of GM-CSF or G-CSF at a dose of 5 g/kg subcutaneously or intravenously over 2 h beginning on day 0 or day 5 following stem cell infusion.
Post-transplant involved-field radiation
Beginning in September 1990, 27 patients referred for transplantation with clinical or radiologic evidence of disease received post-transplant involved-field radiotherapy. These treatments were usually administered within 4 to 8 weeks of discharge and were recommended even if disease areas disappeared after transplant. Treatment was delayed until the neutrophil count exceeded 1000/mm 3 and transfusions were no longer required. The following protocol was developed: patients in complete remission after pretransplant cytoreductive chemotherapy received 20 Gy to areas of previously relapsed disease. Patients with disease at the time of transplant received 30 Gy to these areas as did patients with disease post-transplant. Patients in the latter group were re-evaluated after receiving 30 Gy by physical examination and imaging, and if the tumor size had decreased by this point, then an additional 6-10 Gy was administered based on normal tissue tolerance. The rationale for this step-wise approach was that a stable mass may be largely fibrotic, while a responding mass may contain viable disease.
Statistical methods
For survival analysis, an event was defined as death from any cause or disease relapse or progression. In addition, patients who developed advanced MDS or AML post-transplant or developed a second malignancy (other than basal cell carcinoma of the skin) were considered to have events. The product limit estimator was used to generate survival curves. 16 The log-rank test was used to compare groups. To construct the Cox regression model 16 four variables (disease status, age, salvage response and post-transplant radiation) were identified a priori as likely to be clinically important predictor variables. These four variables were forced into the model, and the six other variables were allowed to enter using a forward step-wise procedure. All P values were two-sided. SAS (SAS Institute, Cary, NC, USA) was used to generate the survival curves and calculate the log-rank statistics. BMD2PL (University of California Press, Berkeley, CA, USA) was used to perform the Cox regressions.
Results
Survival
The 5-year Kaplan-Meier EFS for the entire cohort of 70 patients was 32% (95% Cl: 18-45%) (Figure 1 ). The median follow-up of the 28 patients who did not relapse 2-year event-free survival. EFS = event-free survival; NS = nodular sclerosis; LP = lymphocyte predominant; MC = mixed cellularity; LD = lymphocyte depleted; Post Tx = post-transplant; XRT = involved-field radiation therapy. was 3.6 years (range 0.6-7.6 years). Nine patients survived event-free beyond the 5-year mark. Of the 70 patients, 14 (20%) had non-relapse events, possibly related to the transplant procedure. Thirteen patients died, and their events are summarized in Table 2 . One patient who developed non-Hodgkin's lymphoma (NHL) of the cecum approximately 3.3 years after transplant received treatment and is currently alive 6 years post- transplant. Nine events occurred within 100 days; cardiopulmonary toxicity accounted for eight of these early events. Eight of the nine patients who had early treatmentrelated mortality were transplanted before January 1993. Treatment-related related mortality occurred in only one of 24 (4%) patients transplanted after January 1993.
Of the five patients with late non-relapse events, three developed secondary hematologic malignancies, including AML (one patient) and NHL (two patients) at 3.1, 3.3 and 1.5 years post-transplant. Interestingly, the latter two patients developed NHL involving the cecum. The karyotype of the bone marrow cells in the patient who developed AML was complex (44, XY, ϪY, Ϫ3, Ϫ5, Ϫ7, ϩ11, Ϫ17, Ϫ21, ϩmar1, ϩmar2, ϩmar 3) in all cells.
Twenty-eight patients (40%) relapsed at a median of 5.2 months post-transplant (range 3.6 months to 4.9 years). Only three of the 28 relapses occurred more than 2 years beyond transplant. The majority of relapses occurred at sites of prior disease, but three patients had relapses newly involving the leptomeninges. The majority of patients who had relapses have died; however one patient who developed bulky disease in the abdomen 6 months after transplant was retreated with three cycles of DHAP plus involved-field radiotherapy and remains free of disease progression 7 years after relapse.
Prognostic factors
Variables tested for prognostic significance are listed in Table 3 . In the univariate analysis, significant predictors for improved EFS included: a remission duration of Ͼ6 months; non-refractory disease; minimal disease at the time of transplant; a positive response to pre-transplant chemotherapy; and administration of post-transplant involvedfield radiation. Figure 2 shows the effect of disease status (the strongest predictor) on event-free survival.
As shown in Table 4 , the forward step-wise Cox regression model identified minimal disease status, the administration of post-transplant radiotherapy, and nonrefractory disease as significant independent predictors of improved event-free survival, after adjustment for all other factors. Although the response to pretransplant chemotherapy was significant in the univariate analysis, it was not significant in the Cox model after adjusting for the other predictors.
Effect of post-transplant radiotherapy
The multivariate analysis revealed a significantly better EFS for patients who received post-transplant involvedfield radiotherapy (5 year EFS 44%; 95% Cl: 23-66%) than for those who did not (5 year EFS 26%; 95% Cl 13-41%).
The relationship between post-transplant radiotherapy and event-free survival is shown in Figure 3 , where patients were stratified according to disease status on entry. Of 32 patients who entered with bulky disease, 11 received posttransplant XRT, while 21 patients did not. The 2-year Kaplan-Meier EFS for the 11 patients who received XRT was 40% (95% Cl: 13-71%) as compared to 21% (95% Cl: 7-43%) for the 21 who did not (P = 0.11). Thirty-eight patients entered with minimal disease; of these, 16 patients received post-transplant XRT, while 22 patients did not. The 2-year EFS was 78% (95% Cl: 52-94%) for those who received XRT, as compared to 50% (95% Cl: 30-70%) for those who did not (P = 0.11). Of note, one of nine early treatment-related events occurred in a patient who received post-transplant involved field XRT to the chest, while two of five late non-relapse events occurred in patients who received this treatment. Since patients were not randomly assigned to receive post-transplant involved-field radiotherapy, other factors may have contributed to the observed trends. For example, patients who did not survive long enough to receive XRT would be counted as untreated patients.
To minimize the effect of this time-to-treatment bias, the survival analysis shown in Figure 3 was repeated after excluding patients with early events (рday 50). After this adjustment, which excluded a total of nine patients (all with bulky disease), patients with bulky disease who received post-transplant XRT had a 2-year EFS of 44%, as compared to 35% for untreated patients (P = 0.51). For patients who entered with minimal disease, the 2-year EFS remained 78% for patients who received XRT, as compared to 50% for those who did not (P = 0.11).
Discussion
The 5-year Kaplan-Meier EFS for the cohort of 70 patients presented in this study was 32%. At 3 years, the KaplanMeier EFS was 45%, but five patients had events later than 3 years post-transplant (three relapses, two second malignancies), emphasizing the importance of extended follow-up. The strongest predictor of outcome in the univariate analysis was minimal disease status at time of transplantation. Minimal disease status, non-refractory disease, and administration of post-transplant radiotherapy were independent predictors for improved EFS in the multivariate analysis. These findings corroborate those reported in other studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In addition, several studies have found that a higher number of pretransplant chemotherapy regimens correlated inversely with survival, 3 ,4,7 a variable not specifically examined in this study.
Data from prospective randomized studies comparing autografting with conventional-dose therapy for relapsed or refractory HD are limited. The British National Lymphoma Investigation compared high-dose chemotherapy plus autologous bone marrow transplantation with the same drugs at lower doses not requiring bone marrow rescue in patients with relapsed or refractory HD. 17 Although too few patients were randomized to detect with sufficient power a difference in overall survival at 5 years, there was a benefit in EFS at 3 years (53 vs 10%) favoring the patients that received the high-dose regimen. Specific prognostic factors were not analyzed in this study. In another recent study, historical controls matched for disease stage, age at relapse, and timing of relapse were compared to a series of patients who received high-dose therapy followed by stem cell rescue. 18 While a trend toward improved overall survival was observed for the autografted patients who received highdose therapy, this difference did not achieve statistical significance.
One potential disadvantage to high-dose therapy compared to conventional-dose therapy may be the higher rate of treatment-related mortality. The 100-day treatmentrelated mortality was 13% in this series. The majority of events were due to cardiopulmonary toxicity and occurred prior to 1993. Since 1993, however, the 100-day treatmentrelated mortality rate was only 4% perhaps reflecting improved supportive care, more rapid marrow recovery, or patient selection. Indeed, all patients autografted before 1993 who died from treatment-related toxicity entered transplant with bulky disease. Since the date of transplant was not found to be a significant prognostic factor for event-free survival, bulky-disease state may have accounted for the excess treatment-related mortality seen in those patients autografted before 1993.
Severe or life-threatening cardiopulmonary toxicity following high-dose therapy (in HD or other malignancies) has been reported to occur in up to 40% of patients, with mortality rates up to 20%, depending on the specific conditioning regimen used. 3, 4, [19] [20] [21] In one series of patients with lymphoma, cardiopulmonary toxicity accounted for six deaths among 48 patients who received the BEAC regimen. 21 In our previously reported series of patients with HD and non-Hodgkin's lymphoma, the mortality rate from transplant-related cardiopulmonary toxicity was 12%.
11
Cardiomyopathy appeared to be associated with the use of cyclophosphamide-containing regimens, 11, 20 and was less common in regimens that did not utilize this drug, such as the BEAM regimen (BCNU, etoposide, cytarabine, and melphalan). 3, 5 One review of 63 consecutive autologous transplants using cyclophosphamide-based conditioning regimens in patients with hematologic malignancies found that the incidence of cardiac complications during autotransplantation did not correlate with the dosage and type of anthracycline received during pretransplant treatment. 20 The factors responsible for the development of interstitial pneumonitis were not apparent from our data. One early report described life-threatening pulmonary toxicity in seven of 35 patients who received high-dose BCNU followed by ABMT for solid malignancies. 22 A second report correlated pulmonary toxicity with the dose of BCNU administered: 58% of patients who received 600 mg/m 2 developed symptomatic interstitial pneumonitis, while only 8% of those who received 450 mg/m 2 or less developed this complication. 23 Pretransplant chest radiation was thought to predispose to pneumonitis in one series, 4 but not in another. 19 Three patients in this cohort developed secondary malignancies (one AML and two lymphomas), two of whom have died. An increased incidence of secondary malignancies in long-term survivors of Hodgkin's disease has been well-described. 24, 25 High-dose therapy may also induce secondary malignancies, although the effect of pretransplant therapy is difficult to separate. 26, 27 We could not explain the curious finding of two cases of large cell cecal lymphoma in our series. A retrospective review of primary gastrointestinal lymphoma did not describe any correlation between prior chemoradiotherapy and the development of these extranodal lymphomas. 28 The precise role of involved-field radiotherapy in the post-transplant setting remains unclear. Several non-randomized studies have suggested that post-transplant radiotherapy may be beneficial. [29] [30] [31] One group demonstrated that for patients with persistent disease after high-dose chemotherapy/ABMT, administration of involved field radiotherapy was associated with improved EFS. 30 This study and another also showed that involved-field radiotherapy prevented relapses in previously involved areas. 30, 31 In addition, at least two studies demonstrated that involvedfield radiotherapy may induce durable complete remissions for patients with HD who had residual disease after initial, conventional-dose chemotherapy. 32, 33 In the present analysis, administration of involved-field radiotherapy in the post-transplant setting was significantly associated with improved EFS, even after adjusting for other prognostic factors. When patients were stratified according to minimal or bulky disease status, similar trends toward improved EFS were observed for patients who received involved-field radiotherapy. The lack of statistical significance in this stratification may be due in part to the smaller number of patients in each subgroup. Since patients were not randomly assigned to receive post-transplant involved-field radiotherapy, other factors may have contributed to the observed trends. For example, patients who did not survive long enough to receive radiotherapy were counted as untreated patients. After attempting to adjust for the time-to-treatment selection bias by eliminating patients who had early (Ͻday 50) events, the trend toward improved EFS for patients with minimal disease who received involved-field radiotherapy remained. A prospective, randomized trial may help clarify the role of post-transplant involved-field radiotherapy following autotransplantation for HD.
In summary, this report provides significantly updated outcome data from a single-institution experience of patients autografted for refractory or relapsed Hodgkin's disease using the BEAC regimen. A substantial proportion of the patients had long-term event-free survival. However, the rate of relapse remained high, emphasizing the need to develop new therapeutic strategies.
